Man Group’s Seres Therapeutics MCRB Stock Holding History

Man Group’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-659	Closed	-$63.1K	–	2054
2023 Q2	$63.1K	Buy	+659	New	+$71.7K	﹤0.01%	1906
2021 Q2	–	Sell	-1,007	Closed	-$415K	–	2037
2021 Q1	$415K	Buy	1,007 +552	+121%	+$254K	﹤0.01%	1532
2020 Q4	$223K	Buy	+455	New	+$266K	﹤0.01%	1713

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Man Group's MCRB Position: Q3 2023 in Review

Man Group sold out of Seres Therapeutics (MCRB) in Q3 2023, closing a stake of 659 shares — an estimated $63.1K sold.

Man Group first reported a position in MCRB in Q4 2020 and held it in 3 quarters. The position peaked at $415K in Q1 2021. 134 funds tracked by Wall St. Rank hold MCRB as of Q3 2023.

Man Group reported no remaining Seres Therapeutics position as of Q3 2023 after selling out during the quarter.
Man Group sold 659 Seres Therapeutics shares in Q3 2023, an estimated $63.1K.
Man Group first reported a position in Seres Therapeutics in Q4 2020 and held it in 3 quarters.
Man Group's Seres Therapeutics position peaked at $415K in Q1 2021.
134 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2023.

Based on Man Group's 13F filing for Q3 2023, filed 14 Nov 2023.